GlycoMimetics, Apollomics announce collaboration and license agreement for GMI-1687

This article was originally published here

Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. The companies will also collaborate to advance the preclinical and

The post GlycoMimetics, Apollomics announce collaboration and license agreement for GMI-1687 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply